thalidomide has been researched along with Abnormal Karyotype in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Abnormal Karyotype: A variation from the normal set of chromosomes characteristic of a species.
Excerpt | Relevance | Reference |
---|---|---|
"Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal." | 1.62 | Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. ( Alegre, A; Campana, F; Delimpasi, S; Facon, T; Harrison, SJ; Hulin, C; Inchauspé, M; Macé, S; Perrot, A; Richardson, P; Risse, ML; Simpson, D; Spencer, A; Sunami, K; van de Velde, H; Vlummens, P; Wang, MC; Yong, K, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Harrison, SJ | 1 |
Perrot, A | 1 |
Alegre, A | 1 |
Simpson, D | 1 |
Wang, MC | 1 |
Spencer, A | 1 |
Delimpasi, S | 1 |
Hulin, C | 1 |
Sunami, K | 1 |
Facon, T | 1 |
Vlummens, P | 1 |
Yong, K | 1 |
Campana, F | 1 |
Inchauspé, M | 1 |
Macé, S | 1 |
Risse, ML | 1 |
van de Velde, H | 1 |
Richardson, P | 1 |
Ortega, M | 1 |
Mallo, M | 1 |
Solé, F | 1 |
Sánchez-Morata, C | 1 |
López-Andreoni, L | 1 |
Martínez-Morgado, N | 1 |
Gironella, M | 1 |
Valcárcel, D | 1 |
Vallespí, T | 1 |
2 other studies available for thalidomide and Abnormal Karyotype
Article | Year |
---|---|
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplasti | 2021 |
5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Topics: Abnormal Karyotype; Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Chromo | 2013 |